Meanwhile, the community should start serious and open-minded discussions on the pros and cons associated with germline gene therapy itself—a completely separate issue.

With the approval of CRISPR-based gene editing therapy in December 2023, researchers are able to use CRISPR to promote and restore unstable haemoglobin levels, an essential protein in delivering ...

In December 2017, the US Food & Drug Administration (FDA) approved Luxturna from Spark Therapeutics — the first gene therapy to win market approval in the US. Several other gene therapy programs ...